NZNO welcomes your feedback on PHARMAC’s proposal to list surgical suction, chest and wound drainage devices supplied by LifeHealthcare Limited. The proposal would result in 51 medical devices of the Serres brand being listed.

Please find further consultation information here. If no feedback is received, NZNO will not make a submission.

Please send feedback to PolicyAnalysts@nzno.org.nz by 8 October 2020.

NZNO welcomes your feedback on PHARMAC’s proposal to fund a new treatment, emicizumab (Hemlibra). This is for people with severe haemophilia A and inhibitors to a coagulation (clotting) factor (factor VIII). It is likely that 10 - 15 patients per year would be eligible for treatment under the proposed criteria.

As part of the consultation PHARMAC is also seeking views on whether to risk pool this medicine, which distribution arrangements to use, and what approval process to put in place.

Please find further consultation information here. If no feedback is received, NZNO will not make a submission.

Please send feedback to PolicyAnalysts@nzno.org.nz by 30 September 2020.

NZNO invites your feedback on PHARMAC’s proposal to list medical devices supplied by Cubro Limited:

• 18 non-invasive ventilation products  
• 793 rehabilitation products.

Please find further consultation information here. If no feedback is received, NZNO will not make a submission.

Please send feedback to PolicyAnalysts@nzno.org.nz by Wednesday 30 September 2020.

NZNZO welcomes your feedback on PHARMAC’s proposal to fund two new treatments for type 2 diabetes and amend the contractual terms for one currently funded diabetes treatment through provisional agreements with three suppliers. 

Please find further consultation information here. If no feedback is received, NZNO will not make a submission.

Please send feedback to PolicyAnalysts@nzno.org.nz by 25 September 2020.

NZNO welcomes your feedback on PHARMAC’s proposal to widen access to three funded treatments, adalimumab, etanercept and tocilizumab, for the treatment of juvenile idiopathic arthritis (JIA). This is an inflammatory condition that affects the joints of children and young people. 

Access criteria for adalimumab and etanercept would be widened to include funding for treatment of oligoarticular course JIA and treatment of polyarticular course JIA affecting 5 or more joints. Access criteria for tocilizumab would be widened for polyarticular course JIA affecting 5 or more joints at the same time. 

Further information on the consultation is available here. If no feedback is received, NZNO will not make a submission. 

Please send feedback to PolicyAnalysts@nzno.org.nz by 22 September 2020. 

NZNZO welcomes your feedback on PHARMAC’s proposal to list 91 medical devices supplied by Jackson Allison Medical & Surgical in the following categories:

• obstetrics and gynaecology; and
• rehabilitation equipment, patient positioning products and supports.

Please find further consultation information here. If no feedback is received, NZNO will not make a submission.

Please send feedback to PolicyAnalysts@nzno.org.nz by 23 September 2020.

NZNZO welcomes your feedback on PHARMAC’s proposal to list a range of 346 non-dedicated feeding devices through a non-exclusive provisional agreement with Avanos Medical Australia Pty Ltd.

Please find further consultation information here. If no feedback is received, NZNO will not make a submission.

Please send feedback to PolicyAnalysts@nzno.org.nz by 23 September 2020.

NZNO welcomes your feedback on PHARMAC’s proposal to list a range of 13 respiratory equipment and consumables through a listing agreement with Apex Medical NZ Limited.

Please find further consultation information here. If no feedback is received, NZNO will not make a submission.

Please send feedback to PolicyAnalysts@nzno.org.nz by 24 September 2020.

NZNO warmly invites your feedback on Ministry of Health’s proposed changes to the Primary Maternity Services Notice.

The changes are being made to increase the flexibility of community maternity services to better meet the varied needs of women and their whānau.

Structural and administrative changes to the Notice are proposed. MoH also wants to know our thoughts on the future of maternity services in Aotearoa New Zealand.

A comprehensive discussion document can be seen below.

Information about the consultation is also available here on the MoH website.

Please complete all parts of the attached survey form that are relevant to your role/interests and send your completed form by email to the NZNO policy team. An analyst will collate responses into an NZNO submission.

Please send your feedback to PolicyAnalysts@nzno.org.nz by 6 November 2020.

NZNO welcomes your feedback on PHARMAC’S proposal to list 112 feeding devices under the brand name Medicina.

Please find further consultation information here. If no feedback is received, NZNO will not make a submission.

Please send feedback to PolicyAnalysts@nzno.org.nz by 18 September 2020.

NZNO welcomes your feedback on PHARMAC’S proposal to list 53 Olympus obstetrics and gynaecology devices and 61 endomechanical and electrosurgical devices.

Please find further consultation information here.  If no feedback is received, NZNO will not make a submission

Please send feedback to PolicyAnalysts@nzno.org.nz by 16 September 2020.

The Initial Mental Health and Wellbeing Commission (the ‘Initial Commission’) was established in November 2019 to maintain the momentum of He Ara Oranga, the Government Inquiry into Mental Health and Addiction in Aotearoa while a permanent Commission is established as an independent Crown entity.  Visit the Initial Commission’s website for more information about the role of the Initial Commission.
When established in February 2021, the Commission will oversee the performance of the whole mental health and wellbeing system, provide leadership and support, and challenge it to perform better.

He Ara Oranga wellbeing outcomes framework (attached)
The Initial Commission has been tasked to develop a wellbeing outcomes framework, with relevance to mental health and addiction. The framework is called the 'He Ara Oranga wellbeing outcomes framework' to reflect the pathway to wellness and our role in ensuring the legacy of He Ara Oranga continues.
The purpose of this outcomes framework is to support the mental health and wellbeing system to understand, measure and inform improved outcomes for Aotearoa, at both population (everyone in Aotearoa) and service levels (people and whānau who use mental health and addiction services).
This framework is in development. We are currently focused on the concepts to include in the outcomes framework. Later in the year, we will start the 'data phase' to work through the indicators, measures, data sources and data gaps.

Seeking your views
We are now testing the draft outcomes framework. We are asking for your views on:

• Six areas of wellbeing
• Vision statement
• Our principles

Please provide feedback to sue.gasquoine@nzno.org.nz by Fri Sep 4^th 2020.

The NZ College of Primary Health Care Nurses (NZNO) supports continued nursing education (CNE) providers to ensure our members have access to a library of quality courses, conferences, workshops and online activities that are relevant to primary health care nursing.  This in turn supports members to meet their continuing professional development (CPD) requirements as per Nursing Council NZ (NCNZ) of minimum of 60 hours over a 3-year period (NCNZ 2008).

The NZCPHCN has developed this policy to support applications for endorsement of CNE, which indicates the college has reviewed a CNE activity to ensure it meets the quality criteria of the college.

Further information can be seen here: 
/Portals/0/Files/Documents/Groups/Primary%20Healthcare%20Nurses/2020-08-19%20NZCPHCN%20Endorsment%20of%20Education%20Application%20Form.docx

Please review this policy and provide feedback using track changes Word document or via email text. Please indicate which page/section you are referring to. Individual or group submissions are welcome.

Thank you for your consideration of this proposed policy.

Please send feedback to nicola.thompson@nmdhb.govt.nz by Thursday 10 September 2020.

The NZ College of Primary Health Care Nurses invite you to provide feedback on the Primary Health Care Nurse Position Description. This position description aligns with the Aotearoa NZ Primary Health Care Nurses Standards of Practice. These current Standards of Practice were endorsed in 2019, however the subsequent Position Description, that began development in 2019, has been delayed until now due to COVID-19.

Further information can be seen here:
/Portals/0/Files/Documents/Groups/Primary%20Healthcare%20Nurses/2020-08-19%20Final%20Generic%20PHC%20Nurse%20PD%20Dec%202019.docx 

Please review this document and provide feedback using track changes Word document or via email text. Please indicate which page/section you are referring to. Individual or group submissions are welcome.

NZNO warmly invites your feedback on PHARMAC’s proposal to list two new medicines on the Pharmaceutical Schedule with Special Authority restrictions and Hospital Indication restrictions.

As the Tender process is still in progress, the brand names, pricing and timing for these products to be listed is still to be determined; however, PHARMAC is seeking your feedback on the proposed restrictions for these products:

• Pimecrolimus cream 1% for eczema (atopic dermatitis) on the eyelid
• Tacrolimus ointment 0.1% for eczema (atopic dermatitis) on the face

Further information can be seen here.

Please note the short consultation timeframe.

If the Policy Team receives no feedback, NZNO will not make a submission.

Please send feedback to PolicyAnalysts@nzno.org.nz by 21 August 2020.